Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 9/20 | 1.00 |
| ▸ | NLRP3 | Q96P20 | 2/20 | 1.00 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | TP53 | P04637 | 3/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | STAT6 | P42226 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.46 |
| ▸ | RELA | Q04206 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | THPO | P40225 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Micheliolide SCHEMBL22354429 | 1.00 | PKM (1.00) | PKMNLRP3CYP19A1ALDH1A1LMNA | |
| Micheliolide SCHEMBL22375104 | 1.00 | PKM (1.00) | PKMNLRP3CYP19A1ALDH1A1LMNA | |
| SCHEMBL22388761 | 0.84 | PKM (0.72) | PKMNLRP3CYP19A1ALDH1A1LMNA | |
| SCHEMBL22388763 | 0.84 | PKM (0.72) | PKMNLRP3CYP19A1ALDH1A1LMNA | |
| SCHEMBL24982735 | 0.81 | PKM (0.69) | PKMNLRP3CYP19A1ALDH1A1LMNA | |
| SCHEMBL14900972 | 0.79 | PKM (0.64) | PKMNLRP3CYP19A1ALDH1A1LMNA | |
| SCHEMBL22388762 | 0.78 | PKM (0.63) | PKMNLRP3CYP19A1ALDH1A1LMNA | |
| Ludartin SCHEMBL29556149 | 0.76 | CYP19A1 (1.00) | PKMNLRP3CYP19A1ALDH1A1LMNA | |
| Moroccolide A SCHEMBL31238194 | 0.73 | CYP19A1 (0.60) | PKMNLRP3CYP19A1ALDH1A1LMNA | |
| SCHEMBL18334100 | 0.73 | PKM (0.56) | PKMNLRP3CYP19A1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260091019-A1 | COMPOSITION FOR ENHANCING INCREASING MUSCLE MASS, IMPROVING MUSCULAR FUNCTIONS, OR PREVENTING OR TREATING MUSCULAR DISEASE CONTAINING MICHELIOLIDE | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2026-04-02 | — | — | US | claimed |
| EP-4403559-B1 | GUAIANE SESQUITERPENE POLYMER AND PREPARATION METHOD THEREFOR AND USE THEREOF | KUNMING INST BOTANY CAS (CN) | 2026-01-28 | — | — | EP | claimed |
| EP-4615506-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | Sahin, Fikret (TR) | 2025-09-17 | — | — | EP | claimed |
| WO-2025059108-A1 | THERAPEUTIC COMBINATION AND USE THEREOF FOR TREATING CANCER BY MANIPULATING PYRUVATE KINASE ACTIVITY AND INHIBITING CYSTEINE/CYSTINE METABOLISM | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2025-03-20 | — | — | WO | claimed |
| WO-2024258363-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | SAHIN FIKRET (TR) | 2024-12-19 | — | — | WO | claimed |
| US-20240409552-A1 | GUAIANOLIDE OLIGOMERS, PREPARATION METHOD AND APPLICATION | KUNMING INSTITUTE OF BOTANY, CHINESE ACADEMY OF SCIENCES (CN) | 2024-12-12 | — | — | US | claimed |
| CN-119019353-A | Michelia lactone-cinnamic acid derivative and preparation method and application thereof | 尚德药缘(天津)生物制药有限公司 | 2024-11-26 | — | — | CN | claimed |
| EP-4403559-A1 | GUAIANE SESQUITERPENE POLYMER AND PREPARATION METHOD THEREFOR AND USE THEREOF | Kunming Institute of Botany, Chinese Academy of Sciences (CN) | 2024-07-24 | — | — | EP | claimed |
| US-20230346742-A1 | APPLICATION OF SESQUITERPENE LACTONE IN PREPARING DRUG FOR TREATING OPTIC NEURITIS | Accendatech Luoyang Co., Ltd. (CN) | 2023-11-02 | — | — | US | claimed |
| US-20230293704-A1 | Compositions and Methods for Tendon Regeneration | NATIONAL SCIENCE FOUNDATION | 2023-09-21 | — | — | US | claimed |
| CN-114181225-B | Michelia lactone derivative, pharmaceutical composition, preparation method and application thereof | 上海市第十人民医院 | 2023-08-08 | — | — | CN | claimed |
| EP-4205738-A1 | APPLICATION OF SESQUITERPENE LACTONE IN PREPARING DRUG FOR TREATING OPTIC NEURITIS | Accendatech Luoyang Co., Ltd. (CN) | 2023-07-05 | — | — | EP | claimed |
| CN-111303098-B | Sphaelactone dimethylamine fumarate crystal form E and preparation method thereof | 天津尚德药缘科技股份有限公司 | 2022-10-04 | — | — | CN | claimed |
| CN-111303100-B | Hydrate of michelia lactone dimethylamine fumarate, preparation method and application thereof | 天津尚德药缘科技股份有限公司 | 2022-10-04 | — | — | CN | claimed |
| EP-4747378-A1 | USE OF LET-7B OR MIR-21 INHIBITORS FOR THE TREATMENT INFLAMMATORY BOWEL DISEASES | Institut National de la Santé et de la Recherche Médicale (FR) | 2026-05-27 | — | — | EP | disclosed |
| US-20260091019-A1 | COMPOSITION FOR ENHANCING INCREASING MUSCLE MASS, IMPROVING MUSCULAR FUNCTIONS, OR PREVENTING OR TREATING MUSCULAR DISEASE CONTAINING MICHELIOLIDE | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2026-04-02 | — | — | US | disclosed |
| US-20260091019-A1 | COMPOSITION FOR ENHANCING INCREASING MUSCLE MASS, IMPROVING MUSCULAR FUNCTIONS, OR PREVENTING OR TREATING MUSCULAR DISEASE CONTAINING MICHELIOLIDE | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2026-04-02 | — | — | US | disclosed |
| US-20190314324-A1 | COMBINATION OF MICHELIOLIDE DERIVATIVES OR NANOPARTICLES WITH IONIZING RADIATION AND CHECKPOINT INHIBITORS FOR CANCER THERAPY | THE UNIVERSITY OF CHICAGO | 2019-10-17 | — | — | US | disclosed |
| US-20160367525-A1 | USES OF SESQUITERPENE LACTONE COMPOUNDS AND THEIR DERIVATIVES IN DRUGS PREPARATION | ACCENDATECH (CN) | 2016-12-22 | — | — | US | disclosed |
| US-20160367525-A1 | USES OF SESQUITERPENE LACTONE COMPOUNDS AND THEIR DERIVATIVES IN DRUGS PREPARATION | ACCENDATECH (CN) | 2016-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190314324-A1 | COMBINATION OF MICHELIOLIDE DERIVATIVES OR NANOPARTICLES WITH IONIZING RADIATION AND CHECKPOINT INHIBITORS FOR CANCER THERAPY | MCL1, CD274, PDCD1 | PKM 3247/4885NLRP3 326/4885CYP19A1 4294/4885 |
| US-20260091019-A1 | COMPOSITION FOR ENHANCING INCREASING MUSCLE MASS, IMPROVING MUSCULAR FUNCTIONS, OR PREVENTING OR TREATING MUSCULAR DISEASE CONTAINING MICHELIOLIDE | MYLK2, MYLK, SMN1; SMN2 | PKM 280/4885NLRP3 488/4885CYP19A1 3255/4885 |
| US-20230346742-A1 | APPLICATION OF SESQUITERPENE LACTONE IN PREPARING DRUG FOR TREATING OPTIC NEURITIS | NFKB2, NFKBIA, RPS6KA1 | PKM 4611/4885NLRP3 2227/4885CYP19A1 1198/4885 |
| US-20240409552-A1 | GUAIANOLIDE OLIGOMERS, PREPARATION METHOD AND APPLICATION | HNRNPA2B1, ADM2, GNE | PKM 2775/4885NLRP3 3554/4885CYP19A1 92/4885 |
| US-20160367525-A1 | USES OF SESQUITERPENE LACTONE COMPOUNDS AND THEIR DERIVATIVES IN DRUGS PREPARATION | MCL1, TNF, LSS | PKM 3846/4885NLRP3 745/4885CYP19A1 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.